Show simple item record

dc.contributor.authorNieder, Carsten
dc.contributor.authorMarienhagen, Kirsten
dc.contributor.authorDalhaug, Astrid
dc.contributor.authorNorum, Jan
dc.date.accessioned2013-03-11T09:59:59Z
dc.date.available2013-03-11T09:59:59Z
dc.date.issued2012
dc.description.abstractAccurate prognostic information is desirable when counselling patients with brain metastases regarding their therapeutic options and life expectancy. Based on previous studies, we selected serum lactate dehydrogenase (LDH) as a promising factor on which we perform a pilot study investigating methodological aspects of biomarker studies in patients with brain metastases, before embarking on large-scale studies that will look at a larger number of candidate markers in an expanded patient cohort. For this retrospective analysis, 100 patients with available information on LDH treated with palliative whole-brain radiotherapy were selected. A comprehensive evaluation of different LDH-based variables was performed in uni- and multivariate tests. Probably, the most intriguing finding was that LDH kinetics might be more important, or at least complement, information obtained from a single measurement immediately before radiotherapy. LDH and performance status outperformed several other variables that are part of prognostic models such as recursive partitioning analyses classes and graded prognostic assessment score. LDH kinetics might reflect disease behaviour in extracranial metastatic and primary sites without need for comprehensive imaging studies and is a quite inexpensive diagnostic test. Based on these encouraging results, confirmatory studies in a larger cohort of patients are warranted.en
dc.identifier.citationThe Scientific World Journal (2012), Article ID 609323, 5 ppen
dc.identifier.cristinIDFRIDAID 948165
dc.identifier.doihttp://dx.doi.org/10.1100/2012/609323
dc.identifier.issn1537-744X
dc.identifier.urihttps://hdl.handle.net/10037/4944
dc.identifier.urnURN:NBN:no-uit_munin_4663
dc.language.isoengen
dc.publisherHindawi Publishing Corporationen
dc.rights.accessRightsopenAccess
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en
dc.titleTowards Improved Prognostic Scores Predicting Survival in Patients with Brain Metastases: A Pilot Study of Serum Lactate Dehydrogenase Levelsen
dc.typeJournal articleen
dc.typeTidsskriftartikkelen
dc.typePeer revieweden


File(s) in this item

Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record